866-997-4948(US-Canada Toll Free)

Acne Vulgaris - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Diseases & Conditions

No. of Pages : 177 Pages

Acne Vulgaris - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides an overview of the Acne Vulgaris (Dermatology) pipeline landscape.

Acne vulgaris is a chronic skin disease involving blockage and inflammation of pilosebaceous follicles. Symptoms include crusting of skin bumps, cysts, papules (small red bumps), scarring of the skin and redness around the skin eruptions. The predisposing factors include adolescence, hair gels or oil-based cosmetics, sports equipment such as helmet straps rubbing and occluding skin. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acne Vulgaris - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Acne Vulgaris (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acne Vulgaris (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Acne Vulgaris and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 10, 21, 6, 1, 16, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively.

Acne Vulgaris (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Acne Vulgaris (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Acne Vulgaris (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Acne Vulgaris (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Acne Vulgaris (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Acne Vulgaris (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Acne Vulgaris (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Acne Vulgaris (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acne Vulgaris - Overview 8
Acne Vulgaris - Therapeutics Development 9
Pipeline Overview 9
Pipeline by Companies 10
Pipeline by Universities/Institutes 14
Products under Development by Companies 15
Products under Development by Universities/Institutes 19
Acne Vulgaris - Therapeutics Assessment 20
Assessment by Target 20
Assessment by Mechanism of Action 23
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Acne Vulgaris - Companies Involved in Therapeutics Development 30
3SBio Inc 30
Allergan Plc 30
Almirall SA 31
Biomar Microbial Technologies 31
BioPharmX Inc 32
Braintree Laboratories Inc 32
Brickell Biotech Inc 33
Cassiopea SpA 33
Cell Medica Ltd 34
Cellceutix Corp 34
Celtaxsys Inc 35
Common Pharma Inc 35
Cutanea Life Sciences Inc 36
Dermira Inc 36
ELORAC Inc 37
Ensol Biosciences Inc 37
Foamix Pharmaceuticals Ltd 38
Galderma SA 38
GlaxoSmithKline Plc 39
Helix BioMedix Inc 39
Hovione FarmaCiencia SA 40
Lee's Pharmaceutical Holdings Ltd 40
LEO Pharma A/S 41
Novabiotics Ltd 41
Novan Inc 42
Novartis AG 42
Paratek Pharmaceuticals Inc 43
Pfizer Inc 43
Phosphagenics Ltd 44
Photocure ASA 44
Promius Pharma LLC 45
Provectus Biopharmaceuticals Inc 45
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 46
Sol-Gel Technologies Ltd 46
Sun Pharma Advanced Research Company Ltd 47
Valeant Pharmaceuticals International Inc 47
Vectura Group Plc 48
Vyome Biosciences Pvt Ltd 48
XBiotech Inc 49
Acne Vulgaris - Drug Profiles 50
(adapalene + clindamycin hydrochloride) - Drug Profile 50
(benzoyl peroxide + tretinoin) - Drug Profile 51
(clindamycin phosphate + tretinoin) - Drug Profile 52
acebilustat - Drug Profile 53
Aczone Combo - Drug Profile 57
aminolevulinic acid hydrochloride - Drug Profile 58
AQ-401 - Drug Profile 59
B-244 - Drug Profile 60
BBI-3000 - Drug Profile 62
benzoyl peroxide - Drug Profile 63
BLI-1100 - Drug Profile 64
brilacidin tetrahydrochloride - Drug Profile 65
carbamide peroxide - Drug Profile 76
CB-0301 - Drug Profile 77
CB-0601 - Drug Profile 80
CJM-112 - Drug Profile 81
CLS-007 - Drug Profile 82
dapsone - Drug Profile 83
DFD-10 - Drug Profile 84
DLX-2323 - Drug Profile 85
DLX-2681 - Drug Profile 86
DMT-210 - Drug Profile 87
DMT-310 - Drug Profile 88
DX-0385 - Drug Profile 89
finasteride - Drug Profile 90
FMX-101 - Drug Profile 91
GSK-1940029 - Drug Profile 94
HB-1345 - Drug Profile 95
Hesed-4000 - Drug Profile 96
IB-07A037 - Drug Profile 97
IDP-120 - Drug Profile 98
IDP-121 - Drug Profile 99
IDP-123 - Drug Profile 100
IDP-126 - Drug Profile 101
IDP-129 - Drug Profile 102
IDP-130 - Drug Profile 103
ingenol disoxate - Drug Profile 104
ivermectin - Drug Profile 106
K-1032 - Drug Profile 107
LTA-001 - Drug Profile 108
methyl aminolevulinate hydrochloride - Drug Profile 109
minocycline - Drug Profile 111
minocycline - Drug Profile 112
minocycline hydrochloride - Drug Profile 116
MTC-896 - Drug Profile 117
olumacostat glasaretil - Drug Profile 119
omiganan pentahydrochloride - Drug Profile 124
Peptide to Disrupt Bacterial Cell Membrane and Cell Wall for Acne And Skin Cancer - Drug Profile 126
PF-06423264 - Drug Profile 127
PH-10 - Drug Profile 128
RA-18C3 - Drug Profile 131
sarecycline hydrochloride - Drug Profile 133
SB-204 - Drug Profile 135
SKP-026 - Drug Profile 140
Small Molecule for Acne and Skin Inflammation - Drug Profile 141
Small Molecule to Agonise NR1C3 for Acne Vulgaris - Drug Profile 142
Small Molecules for Acne Vulgaris - Drug Profile 143
Synthetic Peptide for Acne Vulgaris - Drug Profile 144
Synthetic Peptide to Inhibit SREBP1 for Acne, Amyotrophic Lateral Sclerosis and Stroke - Drug Profile 145
tazarotene - Drug Profile 146
tretinoin - Drug Profile 147
tretinoin - Drug Profile 149
trifarotene - Drug Profile 150
Vaccine for Acne Vulgaris - Drug Profile 152
VB-1953 - Drug Profile 153
Acne Vulgaris - Dormant Projects 154
Acne Vulgaris - Discontinued Products 159
Acne Vulgaris - Product Development Milestones 160
Featured News & Press Releases 160
Appendix 171
Methodology 171
Coverage 171
Secondary Research 171
Primary Research 171
Expert Panel Validation 171
Contact Us 171
Disclaimer 172

List of Tables
Number of Products under Development for Acne Vulgaris, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Acne Vulgaris - Pipeline by 3SBio Inc, H1 2017
Acne Vulgaris - Pipeline by Allergan Plc, H1 2017
Acne Vulgaris - Pipeline by Almirall SA, H1 2017
Acne Vulgaris - Pipeline by Biomar Microbial Technologies, H1 2017
Acne Vulgaris - Pipeline by BioPharmX Inc, H1 2017
Acne Vulgaris - Pipeline by Braintree Laboratories Inc, H1 2017
Acne Vulgaris - Pipeline by Brickell Biotech Inc, H1 2017
Acne Vulgaris - Pipeline by Cassiopea SpA, H1 2017
Acne Vulgaris - Pipeline by Cell Medica Ltd, H1 2017
Acne Vulgaris - Pipeline by Cellceutix Corp, H1 2017
Acne Vulgaris - Pipeline by Celtaxsys Inc, H1 2017
Acne Vulgaris - Pipeline by Common Pharma Inc, H1 2017
Acne Vulgaris - Pipeline by Cutanea Life Sciences Inc, H1 2017
Acne Vulgaris - Pipeline by Dermira Inc, H1 2017
Acne Vulgaris - Pipeline by ELORAC Inc, H1 2017
Acne Vulgaris - Pipeline by Ensol Biosciences Inc, H1 2017
Acne Vulgaris - Pipeline by Foamix Pharmaceuticals Ltd, H1 2017
Acne Vulgaris - Pipeline by Galderma SA, H1 2017
Acne Vulgaris - Pipeline by GlaxoSmithKline Plc, H1 2017
Acne Vulgaris - Pipeline by Helix BioMedix Inc, H1 2017
Acne Vulgaris - Pipeline by Hovione FarmaCiencia SA, H1 2017
Acne Vulgaris - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
Acne Vulgaris - Pipeline by LEO Pharma A/S, H1 2017
Acne Vulgaris - Pipeline by Novabiotics Ltd, H1 2017
Acne Vulgaris - Pipeline by Novan Inc, H1 2017
Acne Vulgaris - Pipeline by Novartis AG, H1 2017
Acne Vulgaris - Pipeline by Paratek Pharmaceuticals Inc, H1 2017
Acne Vulgaris - Pipeline by Pfizer Inc, H1 2017
Acne Vulgaris - Pipeline by Phosphagenics Ltd, H1 2017
Acne Vulgaris - Pipeline by Photocure ASA, H1 2017
Acne Vulgaris - Pipeline by Promius Pharma LLC, H1 2017
Acne Vulgaris - Pipeline by Provectus Biopharmaceuticals Inc, H1 2017
Acne Vulgaris - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2017
Acne Vulgaris - Pipeline by Sol-Gel Technologies Ltd, H1 2017
Acne Vulgaris - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2017
Acne Vulgaris - Pipeline by Valeant Pharmaceuticals International Inc, H1 2017
Acne Vulgaris - Pipeline by Vectura Group Plc, H1 2017
Acne Vulgaris - Pipeline by Vyome Biosciences Pvt Ltd, H1 2017
Acne Vulgaris - Pipeline by XBiotech Inc, H1 2017
Acne Vulgaris - Dormant Projects, H1 2017
Acne Vulgaris - Dormant Projects, H1 2017 (Contd..1), H1 2017
Acne Vulgaris - Dormant Projects, H1 2017 (Contd..2), H1 2017
Acne Vulgaris - Dormant Projects, H1 2017 (Contd..3), H1 2017
Acne Vulgaris - Dormant Projects, H1 2017 (Contd..4), H1 2017
Acne Vulgaris - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Acne Vulgaris, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Top 10 Targets, H1 2017
Number of Products by Stage and Top 10 Targets, H1 2017
Number of Products by Top 10 Mechanism of Actions, H1 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Top 10 Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *